Polycystic ovary syndrome with hyperandrogenism as a risk factor for non‐obese non‐alcoholic fatty liver disease

Summary Background Non‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients. Aim To compare the prevalence of non‐obese NAFLD in women with or without PCOS, and to asse...

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 45; no. 11; pp. 1403 - 1412
Main Authors Kim, J. J., Kim, D., Yim, J. Y., Kang, J. H., Han, K. H., Kim, S. M., Hwang, K. R., Ku, S. Y., Suh, C. S., Kim, S. H., Choi, Y. M.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.06.2017
Subjects
Online AccessGet full text
ISSN0269-2813
1365-2036
1365-2036
DOI10.1111/apt.14058

Cover

Abstract Summary Background Non‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients. Aim To compare the prevalence of non‐obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non‐obese Asian cohort. Methods This was a case–control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non‐obese women with PCOS and 892 non‐obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non‐obese women with or without PCOS, and an independent association between non‐obese NAFLD and PCOS. Results Non‐obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non‐obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25–5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status. Conclusions Non‐obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non‐obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non‐obese NAFLD. Linked ContentThis article is linked to Q. Pang et al and L. Zhou and H. Jin paper. To view this article visit https://doi.org/10.1111/apt.14159.
AbstractList Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients. To compare the prevalence of non-obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non-obese Asian cohort. This was a case-control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS. Non-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non-obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25-5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status. Non-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients.BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients.To compare the prevalence of non-obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non-obese Asian cohort.AIMTo compare the prevalence of non-obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non-obese Asian cohort.This was a case-control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS.METHODSThis was a case-control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS.Non-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non-obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25-5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status.RESULTSNon-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non-obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25-5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status.Non-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD.CONCLUSIONSNon-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD.
Linked Content This article is linked to Q. Pang et al and L. Zhou and H. Jin paper. To view this article visit https://doi.org/10.1111/apt.14159 .
BackgroundNon‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients.AimTo compare the prevalence of non‐obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non‐obese Asian cohort.MethodsThis was a case–control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non‐obese women with PCOS and 892 non‐obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non‐obese women with or without PCOS, and an independent association between non‐obese NAFLD and PCOS.ResultsNon‐obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non‐obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25–5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status.ConclusionsNon‐obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non‐obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non‐obese NAFLD.
Summary Background Non‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of NAFLD in obese PCOS patients. Aim To compare the prevalence of non‐obese NAFLD in women with or without PCOS, and to assess an independent association between PCOS and NAFLD in a non‐obese Asian cohort. Methods This was a case–control study using a prospective PCOS cohort. After subjects with other potential causes of chronic liver disease were excluded, 275 non‐obese women with PCOS and 892 non‐obese controls were enrolled. NAFLD was determined by hepatic ultrasonography. Main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non‐obese women with or without PCOS, and an independent association between non‐obese NAFLD and PCOS. Results Non‐obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS (5.5% vs. 2.8%, P = 0.027). PCOS was associated with non‐obese NAFLD (odds ratio: 2.62, 95% confidence intervals: 1.25–5.48) after adjustment for age and body mass index (BMI). In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycaemic status. Conclusions Non‐obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without. In non‐obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non‐obese NAFLD. Linked ContentThis article is linked to Q. Pang et al and L. Zhou and H. Jin paper. To view this article visit https://doi.org/10.1111/apt.14159.
Author Han, K. H.
Kim, S. H.
Kang, J. H.
Suh, C. S.
Kim, J. J.
Ku, S. Y.
Hwang, K. R.
Choi, Y. M.
Kim, D.
Kim, S. M.
Yim, J. Y.
Author_xml – sequence: 1
  givenname: J. J.
  surname: Kim
  fullname: Kim, J. J.
  organization: Seoul National University College of Medicine
– sequence: 2
  givenname: D.
  orcidid: 0000-0003-1919-6800
  surname: Kim
  fullname: Kim, D.
  email: messmd@chol.com
  organization: Stanford University School of Medicine
– sequence: 3
  givenname: J. Y.
  surname: Yim
  fullname: Yim, J. Y.
  organization: Seoul National University Hospital
– sequence: 4
  givenname: J. H.
  surname: Kang
  fullname: Kang, J. H.
  organization: Seoul National University Hospital
– sequence: 5
  givenname: K. H.
  surname: Han
  fullname: Han, K. H.
  organization: Seoul National University Hospital
– sequence: 6
  givenname: S. M.
  surname: Kim
  fullname: Kim, S. M.
  organization: Seoul National University Hospital
– sequence: 7
  givenname: K. R.
  surname: Hwang
  fullname: Hwang, K. R.
  organization: Seoul Municipal Boramae Hospital
– sequence: 8
  givenname: S. Y.
  surname: Ku
  fullname: Ku, S. Y.
  organization: Seoul National University College of Medicine
– sequence: 9
  givenname: C. S.
  surname: Suh
  fullname: Suh, C. S.
  organization: Seoul National University College of Medicine
– sequence: 10
  givenname: S. H.
  surname: Kim
  fullname: Kim, S. H.
  organization: Seoul National University College of Medicine
– sequence: 11
  givenname: Y. M.
  surname: Choi
  fullname: Choi, Y. M.
  organization: Seoul National University College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28370150$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9KHTEYxUNR6tV20RcogW7axWj-TP7MUkRrQdCFXYdM7je9sZnJbZKrzK6P4DP2SRq91420gZCP8DuHw3cO0d4UJ0DoAyXHtJ4Tuy7HtCVCv0ELyqVoGOFyDy0Ik13DNOUH6DDnO0KIVIS9RQdMc0WoIAtUbmKY3ZyLdzje2zTjPE_LFEfAD76s8GpeQ7JPPz9g8nnENmOLk88_8WBdiQkP9dY8f34_xh4y7GYbXFzFUF0HW8qMg7-HhJc-g83wDu0PNmR4v3uP0PeL89uzy-bq-uu3s9OrxnGtdcMHxoWThNDWio4KWsMzKWFoe6K0U9C6rrdSKQWi7XrREm6l6Igm4JSmS36EPm991yn-2kAuZvTZQQh2grjJhmrdUqlaSSv66RV6FzdpqukM7RhrJe8Er9THHbXpR1iadfJj3Zl52WcFTraASzHnBINxvtji41SS9cFQYp4aM7Ux89xYVXx5pXgx_Re7c3_wAeb_g-b05nar-AtXDKaB
CitedBy_id crossref_primary_10_3390_nu13030746
crossref_primary_10_61622_rbgo_2024rbgo81
crossref_primary_10_1111_liv_13735
crossref_primary_10_1002_hep4_1519
crossref_primary_10_1016_j_bbadis_2021_166242
crossref_primary_10_1186_s12902_023_01456_6
crossref_primary_10_3390_biomedicines10010131
crossref_primary_10_1007_s12020_024_04077_8
crossref_primary_10_3390_jcm13144243
crossref_primary_10_1111_jgh_15353
crossref_primary_10_1155_2019_9047324
crossref_primary_10_4103_jrms_JRMS_292_20
crossref_primary_10_3390_diagnostics10110912
crossref_primary_10_11569_wcjd_v30_i1_1
crossref_primary_10_3390_jcm12020451
crossref_primary_10_1111_apt_14401
crossref_primary_10_3390_ijms242316909
crossref_primary_10_1007_s40618_017_0708_9
crossref_primary_10_3390_ijerph16183415
crossref_primary_10_1136_bmjgast_2019_000352
crossref_primary_10_3390_nu16132063
crossref_primary_10_54393_pbmj_v5i7_632
crossref_primary_10_1016_j_jsbmb_2019_105445
crossref_primary_10_5009_gnl19069
crossref_primary_10_3390_metabo13010129
crossref_primary_10_1038_s41598_023_39428_4
crossref_primary_10_4103_joacp_joacp_188_22
crossref_primary_10_1210_endocr_bqac127
crossref_primary_10_3390_jcm12030856
crossref_primary_10_1177_2042018820934319
crossref_primary_10_3389_fendo_2023_1191759
crossref_primary_10_1111_apt_14159
crossref_primary_10_1360_SSV_2023_0194
crossref_primary_10_20945_2359_3997000000242
crossref_primary_10_3390_biomedicines10020249
crossref_primary_10_3350_cmh_2020_0239
crossref_primary_10_1210_clinem_dgab658
crossref_primary_10_3350_cmh_2022_0442
crossref_primary_10_3390_ijms20112720
crossref_primary_10_3390_ijms20112841
crossref_primary_10_7759_cureus_29928
crossref_primary_10_3390_metabo12040298
crossref_primary_10_1007_s12291_022_01042_y
crossref_primary_10_1016_j_phymed_2024_156294
crossref_primary_10_1016_j_diabet_2020_09_007
crossref_primary_10_1002_jgh3_12512
crossref_primary_10_1080_14647273_2019_1709668
crossref_primary_10_1016_j_rbmo_2019_04_002
crossref_primary_10_1016_j_fertnstert_2022_03_020
crossref_primary_10_1016_j_jsbmb_2019_105570
crossref_primary_10_3389_fmolb_2022_888194
crossref_primary_10_3389_fendo_2022_1032361
crossref_primary_10_1097_MD_0000000000032922
crossref_primary_10_3389_fendo_2023_1273542
crossref_primary_10_1038_s41431_020_00712_w
crossref_primary_10_1016_j_aohep_2020_01_004
crossref_primary_10_1016_j_molmet_2020_01_001
crossref_primary_10_1186_s12978_018_0519_2
crossref_primary_10_1016_j_dsx_2018_12_020
crossref_primary_10_3748_wjg_v26_i44_7046
crossref_primary_10_1111_liv_15786
crossref_primary_10_1021_acs_est_3c04419
crossref_primary_10_1007_s11154_020_09621_1
crossref_primary_10_1007_s11695_021_05663_9
crossref_primary_10_3345_cep_2023_00353
crossref_primary_10_1016_j_cld_2018_12_006
crossref_primary_10_1371_journal_pmed_1002542
Cites_doi 10.1155/2015/294278
10.5812/hepatmon.23235
10.1111/apt.13012
10.1002/hep.28697
10.1210/jc.2012-1382
10.1016/j.jhep.2007.04.012
10.1016/j.fertnstert.2008.12.008
10.1111/j.1751-2980.2011.00487.x
10.1111/j.1365-2036.2011.04579.x
10.1016/j.fertnstert.2014.01.049
10.1002/uog.10084
10.1111/j.1365-2036.2011.04724.x
10.1016/j.fertnstert.2004.08.020
10.1038/ajg.2015.235
10.1053/gast.2002.35354
10.1007/s11739-012-0875-9
10.3109/00365513.2010.526242
10.1007/s12020-015-0640-8
10.1210/jc.2009-2698
10.1016/j.jsbmb.2013.04.001
10.1210/jc.2003-032046
10.4103/0974-1208.112370
10.1093/humrep/dep380
10.1210/jc.2005-2774
10.1093/humrep/deq303
10.3346/jkms.2006.21.4.695
10.1093/humrep/des232
10.1210/en.2006-0879
10.1093/humrep/des039
10.1093/humrep/det057
10.1016/S0140-6736(09)61794-3
10.1056/NEJMra041536
10.1093/humrep/den239
10.1093/humrep/deh098
10.1053/j.gastro.2012.04.001
10.1089/met.2012.0147
10.1590/S0004-28032015000200008
10.1016/j.dld.2009.08.002
ContentType Journal Article
Copyright 2017 John Wiley & Sons Ltd
2017 John Wiley & Sons Ltd.
Copyright © 2017 John Wiley & Sons Ltd
Copyright_xml – notice: 2017 John Wiley & Sons Ltd
– notice: 2017 John Wiley & Sons Ltd.
– notice: Copyright © 2017 John Wiley & Sons Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7U9
H94
K9.
M7N
7X8
DOI 10.1111/apt.14058
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Neurosciences Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2036
EndPage 1412
ExternalDocumentID 28370150
10_1111_apt_14058
APT14058
Genre article
Journal Article
GrantInformation_xml – fundername: SNUH Research Fund
  funderid: 04‐2009‐0620
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TR2
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YOC
ZZTAW
~IA
~WT
AAYXX
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7U9
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
M7N
7X8
ID FETCH-LOGICAL-c3888-3f235c60014a59151702266ef4b078c7e4c9ba6777e549b5403a659080ec781d3
IEDL.DBID DR2
ISSN 0269-2813
1365-2036
IngestDate Fri Jul 11 15:51:15 EDT 2025
Fri Jul 25 10:08:45 EDT 2025
Wed Feb 19 02:43:50 EST 2025
Tue Jul 01 02:22:19 EDT 2025
Thu Apr 24 23:08:23 EDT 2025
Wed Jan 22 17:03:43 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3888-3f235c60014a59151702266ef4b078c7e4c9ba6777e549b5403a659080ec781d3
Notes Linked Content
https://doi.org/10.1111/apt.14159
.
This article is linked to Q. Pang et al and L. Zhou and H. Jin paper. To view this article visit
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1919-6800
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.14058
PMID 28370150
PQID 1922463953
PQPubID 2045200
PageCount 10
ParticipantIDs proquest_miscellaneous_1884167461
proquest_journals_1922463953
pubmed_primary_28370150
crossref_citationtrail_10_1111_apt_14058
crossref_primary_10_1111_apt_14058
wiley_primary_10_1111_apt_14058_APT14058
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2017
2017-06-00
2017-Jun
20170601
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: June 2017
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
PublicationTitle Alimentary pharmacology & therapeutics
PublicationTitleAlternate Aliment Pharmacol Ther
PublicationYear 2017
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2012; 142
2006; 91
2013; 28
2005; 352
2017; 65
2015; 52
2004; 89
2011; 33
2016; 51
2011; 34
2011; 12
2012; 39
2005; 83
2013; 8
2013; 6
2012; 97
2010; 42
2010; 25
2013; 11
2000
2004; 19
2006; 21
2013; 138
2015; 41
2015; 110
2002; 123
2010; 375
2014; 14
2008; 23
2016
2008; 43
2015
2012; 27
2011; 26
2010; 70
2007; 47
2010; 95
2014; 101
2006; 147
2010; 93
e_1_2_7_6_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
Qu Z (e_1_2_7_16_1) 2013; 11
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
World Health Organization Western Pacific Region (e_1_2_7_27_1) 2000
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
Kim D (e_1_2_7_5_1) 2016
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
Zheng RH (e_1_2_7_12_1) 2008; 43
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
28776742 - Aliment Pharmacol Ther. 2017 Sep;46(5):566-567
References_xml – volume: 97
  start-page: 3709
  year: 2012
  end-page: 16
  article-title: Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance
  publication-title: J Clin Endocrinol Metab
– volume: 142
  start-page: 1592
  year: 2012
  end-page: 609
  article-title: The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
  publication-title: Gastroenterology
– volume: 138
  start-page: 100
  year: 2013
  end-page: 6
  article-title: Androgen (dihydrotestosterone)‐mediated regulation of food intake and obesity in female mice
  publication-title: J Steroid Biochem Mol Biol
– volume: 91
  start-page: 1741
  year: 2006
  end-page: 7
  article-title: Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome
  publication-title: J Clin Endocrinol Metab
– volume: 39
  start-page: 341
  year: 2012
  end-page: 7
  article-title: Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome
  publication-title: Ultrasound Obstet Gynecol
– volume: 25
  start-page: 212
  year: 2010
  end-page: 20
  article-title: Increased androgen bioavailability is associated with non‐alcoholic fatty liver disease in women with polycystic ovary syndrome
  publication-title: Hum Reprod
– volume: 65
  start-page: 54
  year: 2017
  end-page: 64
  article-title: Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
  publication-title: Hepatology
– volume: 27
  start-page: 1439
  year: 2012
  end-page: 44
  article-title: Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome
  publication-title: Hum Reprod
– volume: 14
  start-page: e23235
  year: 2014
  article-title: Are women with polycystic ovarian syndrome at a high risk of non‐alcoholic fatty liver disease; a meta‐analysis
  publication-title: Hepat Mon
– volume: 26
  start-page: 214
  year: 2011
  end-page: 20
  article-title: Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre‐employment physical check‐up
  publication-title: Hum Reprod
– volume: 23
  start-page: 1924
  year: 2008
  end-page: 31
  article-title: Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women
  publication-title: Hum Reprod
– volume: 34
  start-page: 274
  year: 2011
  end-page: 85
  article-title: Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
  publication-title: Aliment Pharmacol Ther
– volume: 70
  start-page: 554
  year: 2010
  end-page: 60
  article-title: Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age
  publication-title: Scand J Clin Lab Invest
– volume: 6
  start-page: 9
  year: 2013
  end-page: 14
  article-title: Prevalence of hepatic steatosis in women with polycystic ovary syndrome
  publication-title: J Hum Reprod Sci
– volume: 51
  start-page: 211
  year: 2016
  end-page: 21
  article-title: Evidence that non‐alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato‐ovarian axis?
  publication-title: Endocrine
– start-page: 15
  year: 2000
  end-page: 21
– volume: 43
  start-page: 98
  year: 2008
  end-page: 101
  article-title: Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case‐control study
  publication-title: Zhonghua Fu Chan Ke Za Zhi
– volume: 41
  start-page: 65
  year: 2015
  end-page: 76
  article-title: Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey
  publication-title: Aliment Pharmacol Ther
– year: 2015
  article-title: Sex hormones and their receptors regulate liver energy homeostasis
  publication-title: Int J Endocrinol
– volume: 12
  start-page: 125
  year: 2011
  end-page: 30
  article-title: Relationship between nonalcoholic fatty liver disease and metabolic syndrome
  publication-title: J Dig Dis
– volume: 352
  start-page: 1223
  year: 2005
  end-page: 36
  article-title: Polycystic ovary syndrome
  publication-title: N Engl J Med
– volume: 47
  start-page: 412
  year: 2007
  end-page: 7
  article-title: Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
  publication-title: J Hepatol
– volume: 52
  start-page: 117
  year: 2015
  end-page: 23
  article-title: Prevalence of non‐alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome
  publication-title: Arq Gastroenterol
– year: 2016
  article-title: Nonobese fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
– volume: 101
  start-page: 1424
  year: 2014
  end-page: 30
  article-title: Complete phenotype and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome
  publication-title: Fertil Steril
– volume: 89
  start-page: 2745
  year: 2004
  end-page: 9
  article-title: The prevalence and features of the polycystic ovary syndrome in an unselected population
  publication-title: J Clin Endocrinol Metab
– volume: 83
  start-page: 494
  year: 2005
  end-page: 7
  article-title: Abnormal aminotransferase activity in women with polycystic ovary syndrome
  publication-title: Fertil Steril
– volume: 147
  start-page: 5907
  year: 2006
  end-page: 13
  article-title: Regulation of adenosine 5’, monophosphate‐activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen‐deficient state
  publication-title: Endocrinology
– volume: 123
  start-page: 745
  year: 2002
  end-page: 50
  article-title: The utility of radiological imaging in nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 8
  start-page: 265
  year: 2013
  end-page: 7
  article-title: Hepatic steatosis index and lipid accumulation product as middle‐term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study
  publication-title: Intern Emerg Med
– volume: 27
  start-page: 3067
  year: 2012
  end-page: 73
  article-title: Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria
  publication-title: Hum Reprod
– volume: 21
  start-page: 695
  year: 2006
  end-page: 700
  article-title: Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non‐diabetic adults
  publication-title: J Korean Med Sci
– volume: 11
  start-page: 725
  year: 2013
  end-page: 32
  article-title: The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS
  publication-title: Iran J Reprod Med
– volume: 95
  start-page: 3332
  year: 2010
  end-page: 41
  article-title: Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome
  publication-title: J Clin Endocrinol Metab
– volume: 19
  start-page: 41
  year: 2004
  end-page: 7
  article-title: Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS)
  publication-title: Hum Reprod
– volume: 110
  start-page: 1306
  year: 2015
  end-page: 14
  article-title: Prevalence and severity of nonalcoholic fatty liver disease in non‐obese patients: a population study using proton‐magnetic resonance spectroscopy
  publication-title: Am J Gastroenterol
– volume: 93
  start-page: 1220
  year: 2010
  end-page: 6
  article-title: Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome
  publication-title: Fertil Steril
– volume: 42
  start-page: 503
  year: 2010
  end-page: 8
  article-title: Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease
  publication-title: Dig Liver Dis
– volume: 375
  start-page: 181
  year: 2010
  end-page: 3
  article-title: The metabolic syndrome
  publication-title: Lancet
– volume: 28
  start-page: 1354
  year: 2013
  end-page: 60
  article-title: Atherogenic changes in low‐density lipoprotein particle profiles were not observed in non‐obese women with polycystic ovary syndrome
  publication-title: Hum Reprod
– volume: 33
  start-page: 801
  year: 2011
  end-page: 14
  article-title: Systematic review:association of polycystic ovary syndrome with metabolic syndrome and non‐alcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
– volume: 11
  start-page: 412
  year: 2013
  end-page: 6
  article-title: Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study
  publication-title: Metab Syndr Relat Disord
– ident: e_1_2_7_39_1
  doi: 10.1155/2015/294278
– ident: e_1_2_7_17_1
  doi: 10.5812/hepatmon.23235
– ident: e_1_2_7_3_1
  doi: 10.1111/apt.13012
– ident: e_1_2_7_6_1
  doi: 10.1002/hep.28697
– volume: 11
  start-page: 725
  year: 2013
  ident: e_1_2_7_16_1
  article-title: The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS
  publication-title: Iran J Reprod Med
– ident: e_1_2_7_36_1
  doi: 10.1210/jc.2012-1382
– ident: e_1_2_7_11_1
  doi: 10.1016/j.jhep.2007.04.012
– ident: e_1_2_7_19_1
  doi: 10.1016/j.fertnstert.2008.12.008
– ident: e_1_2_7_4_1
  doi: 10.1111/j.1751-2980.2011.00487.x
– ident: e_1_2_7_35_1
  doi: 10.1111/j.1365-2036.2011.04579.x
– ident: e_1_2_7_10_1
  doi: 10.1016/j.fertnstert.2014.01.049
– ident: e_1_2_7_14_1
  doi: 10.1002/uog.10084
– ident: e_1_2_7_2_1
  doi: 10.1111/j.1365-2036.2011.04724.x
– ident: e_1_2_7_40_1
  doi: 10.1016/j.fertnstert.2004.08.020
– ident: e_1_2_7_7_1
  doi: 10.1038/ajg.2015.235
– ident: e_1_2_7_31_1
  doi: 10.1053/gast.2002.35354
– ident: e_1_2_7_42_1
  doi: 10.1007/s11739-012-0875-9
– year: 2016
  ident: e_1_2_7_5_1
  article-title: Nonobese fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
– ident: e_1_2_7_21_1
  doi: 10.3109/00365513.2010.526242
– ident: e_1_2_7_22_1
  doi: 10.1007/s12020-015-0640-8
– ident: e_1_2_7_20_1
  doi: 10.1210/jc.2009-2698
– start-page: 15
  volume-title: International Association for the Study of Obesity Task Force: The Asia‐Pacific Perspective: Redefining Obesity and its Treatment
  year: 2000
  ident: e_1_2_7_27_1
– ident: e_1_2_7_38_1
  doi: 10.1016/j.jsbmb.2013.04.001
– ident: e_1_2_7_8_1
  doi: 10.1210/jc.2003-032046
– ident: e_1_2_7_15_1
  doi: 10.4103/0974-1208.112370
– ident: e_1_2_7_13_1
  doi: 10.1093/humrep/dep380
– ident: e_1_2_7_41_1
  doi: 10.1210/jc.2005-2774
– ident: e_1_2_7_29_1
  doi: 10.1093/humrep/deq303
– ident: e_1_2_7_34_1
  doi: 10.3346/jkms.2006.21.4.695
– ident: e_1_2_7_23_1
  doi: 10.1093/humrep/des232
– ident: e_1_2_7_37_1
  doi: 10.1210/en.2006-0879
– ident: e_1_2_7_24_1
  doi: 10.1093/humrep/des039
– ident: e_1_2_7_25_1
  doi: 10.1093/humrep/det057
– ident: e_1_2_7_33_1
  doi: 10.1016/S0140-6736(09)61794-3
– ident: e_1_2_7_9_1
  doi: 10.1056/NEJMra041536
– ident: e_1_2_7_30_1
  doi: 10.1093/humrep/den239
– ident: e_1_2_7_28_1
  doi: 10.1093/humrep/deh098
– ident: e_1_2_7_26_1
  doi: 10.1053/j.gastro.2012.04.001
– ident: e_1_2_7_43_1
  doi: 10.1089/met.2012.0147
– volume: 43
  start-page: 98
  year: 2008
  ident: e_1_2_7_12_1
  article-title: Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case‐control study
  publication-title: Zhonghua Fu Chan Ke Za Zhi
– ident: e_1_2_7_18_1
  doi: 10.1590/S0004-28032015000200008
– ident: e_1_2_7_32_1
  doi: 10.1016/j.dld.2009.08.002
– reference: 28776742 - Aliment Pharmacol Ther. 2017 Sep;46(5):566-567
SSID ssj0006702
Score 2.4849257
Snippet Summary Background Non‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies...
Linked Content This article is linked to Q. Pang et al and L. Zhou and H. Jin paper. To view this article visit https://doi.org/10.1111/apt.14159 .
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the prevalence of...
BackgroundNon‐alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS). However, most studies investigated the...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1403
SubjectTerms Adult
Androgens - metabolism
Body mass
Body mass index
Case-Control Studies
Fatty liver
Female
Humans
Hyperandrogenism - etiology
Insulin
Insulin Resistance
Liver diseases
Non-alcoholic Fatty Liver Disease - epidemiology
Non-alcoholic Fatty Liver Disease - etiology
Polycystic ovary syndrome
Polycystic Ovary Syndrome - complications
Prevalence
Prospective Studies
Risk Factors
Testosterone
Ultrasonic imaging
Ultrasound
Title Polycystic ovary syndrome with hyperandrogenism as a risk factor for non‐obese non‐alcoholic fatty liver disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.14058
https://www.ncbi.nlm.nih.gov/pubmed/28370150
https://www.proquest.com/docview/1922463953
https://www.proquest.com/docview/1884167461
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDiWXvtI226RFKT3k4mBbsrRLT6FtCIWEUBLIIWBGskxDtuul9gY2p_yE_sb-ks7IjzR9QOjN2LIkSzPWN5rRNwBv43FRxk6mkVcJRgqLSTTWSkfGllImzMjt-IDz4ZE-OFWfzrKzFXjXn4Vp-SGGDTfWjPC_ZgVHW_-i5DhvSM3jjA_6JlIzb_6Hz7fUUdqEeEMyMSZROk5kxyrEUTzDm3fXoj8A5l28Ghac_Udw3ne1jTO53F00dtdd_8bi-J_f8hgedkBU7LWS8wRW_OwpPDjsXO3r0BxX06VbMo2zqK6oatGTGwjeuxVfyICldY7ukAhe1F8F1gIFR6qLNoePIDgsZtXsx833yvrad9fY5uSlWktsmqWYcmCI6PxEz-B0_-PJ-4OoS9EQOUm2cyTLVGaOQZPCbELogUadlnxfKkvYwxmv3MSiNsZ4MkQtwUOJmtOsx94ZgsryOaxS634DBNq0QJNmiATRPBok6FooH5u01BirYgQ7_WTlruMv5zQa07y3Y2gU8zCKI3gzFJ23pB1_K7TVz3je6W2dE95NFYG2TI5ge3hMGsduFJz5akFlxuyqNUonI3jRSsrQSuASIoxNnQ3z_e_m873jk3Dx8v5FN2EtZVQRNoG2YLX5tvCvCBM19nUQ_p9xEwlZ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlUovUMqj29LWVBx6CcrGTpyVekEItG1ZhKpF4lJFE8cRiO0GdbNIy4mf0N_YX9IZ50Fpi4S4RYljO7Yn_ubhbwC2_TjLfSMDz6ouegqznhdHKvJ0mkvZZUZuwwecB0dR_0R9Pg1P5-Bjcxam4odoDW4sGe5_zQLOBuk_pBwvS5JzP4zn4YnzzzEk-npLHhVpF3FISkbPC-KurHmFOI6nffXubvQPxLyLWN2Wc7AM35rOVpEmFzvTMt0x13_xOD72a57DUo1FxW61eFZgzo5fwNNB7W1fhfK4GM3MjJmcRXFFdYuG30Cw-VackQ5LWx3doVV4PvkucCJQcLC6qNL4CELEYlyMf938LFI7sfU1Vml5qdYcy3ImRhwbImpX0RqcHOwP9_penaXBM5LUZ0_mgQwN4yaFYY8ABA077fo2VynBD6OtMr0UI621JV00JYQoMeJM6741mtCyXIcFat2-BIFpkKEOQkRCaRY1EnrNlPV1kEfoq6wDH5rZSkxNYc6ZNEZJo8rQKCZuFDvwvi16WfF2_K_QZjPlSS26k4Qgb6AIt4WyA1vtYxI69qTg2BZTKhOzt1arqNuBjWqptK04OiGC2dRZN-H3N5_sHg_dxauHF30Hi_3h4DA5_HT05TU8CxhkOJvQJiyUP6b2DUGkMn3rJOE3-TMNdw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB5tQUK9UEpbWH6KW_XAJSgbO3ZWnFbACkpBqwokDpWiieMIxLJZsdlK21MfgWfkSRg7Py3QSlVvUeLYju3JfOMZfwPwyY_SzNc88IzooCcw7XqRFNJTScZ5xzJya3vA-eRUHp6LzxfhRQt267MwJT9Es-FmJcP9r62Aj9PsNyHHcUFi7ofRC5gXktSkRURff3FHSeUCDsnG6HpB1OEVrZAN42lefayMniHMx4DVaZz-K_hW97UMNLnemRbJjv7xhMbxPz9mCRYrJMp65dJ5DS0zWoaFk8rX_gaKQT6c6ZnlcWb5d6qa1ewGzG7eskuyYEnR0R1ag1eTG4YThsyGqrMyiQ8jPMxG-ej-512emImprrFMyku1ZlgUMza0kSGschS9hfP-wdneoVflaPA0J-PZ41nAQ21Rk8CwS_CBRp10vslEQuBDKyN0N0GplDJkiSaEDzlKm2fdN1oRVubvYI5aN6vAMAlSVEGISBjNoELCrqkwvgoyib5I27BdT1asKwJzm0djGNeGDI1i7EaxDR-bouOSteNPhTbqGY8rwZ3EBHgDQagt5G340DwmkbN-FByZfEplIuurVUJ22rBSrpSmFUcmRCCbOuvm--_Nx73BmbtY-_eiW7Aw2O_HX45Oj9fhZWARhtsQ2oC54nZqNgkfFcl7JwcP0JsMJg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polycystic+ovary+syndrome+with+hyperandrogenism+as+a+risk+factor+for+non-obese+non-alcoholic+fatty+liver+disease&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Kim%2C+J+J&rft.au=Kim%2C+D&rft.au=Yim%2C+J+Y&rft.au=Kang%2C+J+H&rft.date=2017-06-01&rft.eissn=1365-2036&rft.volume=45&rft.issue=11&rft.spage=1403&rft_id=info:doi/10.1111%2Fapt.14058&rft_id=info%3Apmid%2F28370150&rft.externalDocID=28370150
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon